This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IceCure Medical 미래 성장

Future 기준 확인 2/6

현재 IceCure Medical 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

32.8%

수익 성장률

n/a

EPS 성장률

Medical Equipment 수익 성장	22.3%
매출 성장률	47.5%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	24 Jul 2023

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

TASE:ICCM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	36	-1	-13	N/A	2
12/31/2024	11	-14	-21	N/A	4
12/31/2023	5	-16	-17	-15	4
3/31/2023	3	-16	-15	-14	N/A
12/31/2022	3	-17	-15	-14	N/A
9/30/2022	4	-16	-17	-16	N/A
6/30/2022	4	-15	-17	-16	N/A
3/31/2022	3	-13	-14	-14	N/A
12/31/2021	4	-10	-13	-13	N/A
9/30/2021	4	-8	-9	-8	N/A
6/30/2021	4	-6	-7	-6	N/A
3/31/2021	4	-4	-5	-5	N/A
12/31/2020	4	-4	-4	-4	N/A
9/30/2020	3	-4	-2	-2	N/A
6/30/2020	3	-4	-1	0	N/A
3/31/2020	2	-4	-1	-1	N/A
12/31/2019	2	-5	-2	-2	N/A
9/30/2019	1	-5	N/A	N/A	N/A
6/30/2019	1	-4	-4	-4	N/A
3/31/2019	1	-4	-4	-4	N/A
12/31/2018	1	-4	-3	-3	N/A
9/30/2018	1	-3	N/A	N/A	N/A
6/30/2018	1	-3	-3	-3	N/A
3/31/2018	1	-3	-3	-3	N/A
12/31/2017	1	-3	-3	-3	N/A
9/30/2017	1	-3	-3	-3	N/A
6/30/2017	1	-3	-3	-3	N/A
3/31/2017	1	-3	-3	-3	N/A
12/31/2016	1	-3	N/A	-3	N/A
9/30/2016	1	-3	N/A	-3	N/A
6/30/2016	1	-4	N/A	-4	N/A
3/31/2016	1	-4	N/A	-3	N/A
12/31/2015	1	-4	N/A	-3	N/A
9/30/2015	1	-4	N/A	-3	N/A
6/30/2015	1	-4	N/A	-3	N/A
3/31/2015	1	-4	N/A	-3	N/A
12/31/2014	1	-5	N/A	-3	N/A
9/30/2014	1	-5	N/A	-4	N/A
6/30/2014	1	-5	N/A	-4	N/A
3/31/2014	0	-5	N/A	-3	N/A
12/31/2013	0	-5	N/A	-3	N/A
9/30/2013	0	-5	N/A	-4	N/A
6/30/2013	0	-5	N/A	-4	N/A
3/31/2013	0	-5	N/A	-4	N/A
12/31/2012	0	-5	N/A	-4	N/A
9/30/2012	0	-4	N/A	-4	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ICCM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ICCM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ICCM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ICCM 의 수익(연간 47.5% ) IL 시장( 1.9% 보다 빠르게 성장할 것으로 예상됩니다. 1.9% 연간).

고성장 수익: ICCM 의 수익(연간 47.5% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ICCM 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

This company listing is no longer active

IceCure Medical 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.35 loss in FY 2021)

Here's Why We're Watching IceCure Medical's (TLV:ICCM) Cash Burn Situation

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.091 loss in 3Q 2021)

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

Are Investors Undervaluing IceCure Medical Ltd (TLV:ICCM) By 29%?

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020)

Is IceCure Medical Ltd (TLV:ICCM) Potentially Undervalued?

IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022

Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump

Is IceCure Medical (TLV:ICCM) In A Good Position To Deliver On Growth Plans?

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

Icecure Medical Ordinary Shares Deleted from Other OTC

IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting

Full year 2020 earnings released: ₪0.11 loss per share (vs ₪0.15 loss in FY 2019)

IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East

New 90-day high: ₪1.48

New 90-day high: ₪0.70

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

New 90-day high: ₪0.72

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

IceCure Medical Ltd has completed a Follow-on Equity Offering in the amount of ILS 20.7 million.

New 90-day low - ₪0.52

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견